

Supplementary Table 4 – Mechanism-oriented plasma biomarkers

	Empagliflozin (n = 22)		Sitagliptin (n = 22)		p value
	Baseline	Follow-up	Baseline	Follow-up	
<i>hsCRP (mg/dL)</i>	0.114 (0.026-0.216)	0.095 (0.048-0.153)	0.177 (0.090-0.762)	0.156 (0.081-0.405)	ns
<i>BNP (pg/mL)</i>	25 (10-47)	16 (10-46)	12 (10-25)	11 (10-20)	ns
<i>NT-proBNP (pg/mL)</i>	63 (28-131)	54 (26-134)	26 (16-76)	35 (26-53)	ns
<i>TnHS (ng/mL)</i>	9.9 (6.7-16.4)	10.0 (7.6-13.9)	7.8 (5.8-27.0)	8.2 (6.6-15.2)	ns
<i>proADM (nmol/L)</i>	0.080 ± 0.065	0.150 ± 0.120	0.154 ± 0.198	0.119 ± 0.130	na
<i>NT-PRO3 (ng/mL)</i>	5.6 (4.4-6.7)	5.6 (4.0-7.7)	6.7 (5.1-8.9)	6.2 (4.7-7.6)	ns
<i>TNFα (pg/mL)</i>	0.74 (0.46-0.96)	0.79 (0.69-0.96)	0.67 (0.59-0.88)	0.80 (0.66-0.93)	ns

Tumor necrosis factor-alpha (TNFa) and high-sensitive c-reactive protein (hsCRP) myeloperoxidase (MPO), brain natriuretic peptide (BNO) and N-terminal pro-BNO (NT-pro BNP), pro-adrenomedullin (proADM), high-sensitive troponin T (hsTnT), NT procollagen 3 (NT-PRO3) p value indicates the results of the ANOVA for repeated measures results of the time*treatment interaction term